Engagement With a Remote Symptom-Tracking Platform Among Participants With Major Depressive Disorder: Randomized Controlled Trial.

"Conflicts of Interest: MH is the principal investigator of the RADAR-CNS consortium, a private-public precompetitive consortium with research funding from Janssen, Union Chimique Belge, Merck Sharp & Dohme, Biogen, and Lundbeck. All other authors declare no other conflicts of interest."

"The Remote Assessment of Disease and Relapse–Central Nervous System project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement number 115902. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations (EFPIA). This communication reflects the views of the RADAR-CNS consortium, and neither Innovative Medicines Initiative nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The funding body was not involved in the design of the study or the collection, analysis, or interpretation of the data. This research was reviewed by a team with experience of mental health problems and their carers who were specially trained to advise on research proposals and documentation through the Feasibility and Acceptability Support Team for Researchers: a free, confidential service in England provided by the NIHR Maudsley Biomedical Research Centre via King’s College London and South London and Maudsley NHS Foundation Trust. Finally, the authors would like to thank all members of the RADAR-CNS patient advisory board who have experience of living with or supporting those who are living with depression, epilepsy, or multiple sclerosis."

"Trial Registration ClinicalTrials.gov NCT04972474; https://clinicaltrials.gov/ct2/show/NCT04972474"